TY - JOUR
T1 - Neurodevelopmental and Epilepsy Phenotypes in Individuals With Missense Variants in the Voltage-Sensing and Pore Domains of KCNH5
AU - Happ, Hannah C.
AU - Sadleir, Lynette G.
AU - Zemel, Matthew
AU - De Valles-Ibáñez, Guillem
AU - Hildebrand, Michael S.
AU - McConkie-Rosell, Allyn
AU - McDonald, Marie
AU - May, Halie
AU - Sands, Tristan
AU - Aggarwal, Vimla
AU - Elder, Christopher
AU - Feyma, Timothy
AU - Bayat, Allan
AU - Møller, Rikke S.
AU - Fenger, Christina D.
AU - Klint Nielsen, Jens Erik
AU - Datta, Anita N.
AU - Gorman, Kathleen M.
AU - King, Mary D.
AU - Linhares, Natalia D.
AU - Burton, Barbara K.
AU - Paras, Andrea
AU - Ellard, Sian
AU - Rankin, Julia
AU - Shukla, Anju
AU - Majethia, Purvi
AU - Olson, Rory J.
AU - Muthusamy, Karthik
AU - Schimmenti, Lisa A.
AU - Starnes, Keith
AU - Sedlacková, Lucie
AU - Štěrbová, Katalin
AU - Vlčková, Markéta
AU - Laššuthová, Petra
AU - Jahodová, Alena
AU - Porter, Brenda E.
AU - Couque, Nathalie
AU - Colin, Estelle
AU - Prouteau, Clément
AU - Collet, Corinne
AU - Smol, Thomas
AU - Caumes, Roseline
AU - Vansenne, Fleur
AU - Bisulli, Francesca
AU - Licchetta, Laura
AU - Person, Richard
AU - Torti, Erin
AU - McWalter, Kirsty
AU - Webster, Richard
AU - Gerard, Elizabeth E.
AU - Lesca, Gaetan
AU - Szepetowski, Pierre
AU - Scheffer, Ingrid E.
AU - Mefford, Heather C.
AU - Carvill, Gemma L.
N1 - Funding Information:
The authors thank the patients and their families for participating in our research study. They also thank Jennifer Kearney for her valuable insight on ion channel genetics. They thank the Epi25 principal investigators, local staff from individual cohorts, and all patients with epilepsy who participated in the study for making possible this global collaboration and resource to advance epilepsy genetics research. This work is part of the Centers for Common Disease Genomics (CCDG) program, funded by the National Human Genome Research Institute (NHGRI) and the National Heart, Lung, and Blood Institute (NHLBI). CCDG-funded Epi25 research activities at the Broad Institute, including genomic data generation in the Broad Genomics Platform, are supported by NHGRI grant UM1 HG008895 (PIs: Eric Lander, Stacey Gabriel, Mark Daly, and Sekar Kathiresan). The Genome Sequencing Program efforts were also supported by NHGRI grant 5U01HG009088-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors thank the Stanley Center for Psychiatric Research at the Broad Institute for supporting the genomic data generation efforts.
Funding Information:
L.G. Sadleir is a consultant for the Epilepsy Consortium and has received travel grants from Seqirus and Nutricia. She has received research grants and consultancy fees from Zynerba Pharmaceuticals. She has served on an Eisai Pharmaceuticals scientific advisory panel. R. Person, E. Torti, and K. McWalter are employees of GeneDx. B.K. Burton has received consulting fees and/or honoraria from Aeglea, Alexion, Applied Therapeutics, BioMarin, Capsida, Denali, Horizon, JCR Pharma, Moderna, SIO, Takeda, and Ultragenyx and has conducted clinical trials funded by BioMarin, Denali, JCR Pharma, Homology Medicines, Sangamo, and Ultragenyx. I.E. Scheffer has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, RogCon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, BioMarin, and Eisai; has served as an investigator for Anavex Life Sciences, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenix, ES Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix, and Zynerba; has consulted for Atheneum Partners, Care Beyond Diagnosis, Epilepsy Consortium, Ovid Therapeutics, UCB, and Zynerba Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited. She may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies; and has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). The remaining authors have nothing relevant to disclose. Go to Neurology.org/N for full disclosures.
Funding Information:
This work was supported by funding from the NIH (NINDS NS069605). H.C. Mefford is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists. G.L. Carvill was funded by the Citizens United for Research in Epilepsy (CURE) Taking Flight Award and NIH (NINDS NS089858). I.E. Scheffer is supported by a National Health and Medical Research Council of Australia (NHMRC) Program grant, Investigator grant, as well as a Centre of Research Excellence and Synergy grant. L.G. Sadleir and G. Valles-Ibáñez were supported by Health Research Council of New Zealand and Cure Kids research grants. L. Sedlackova, K. Sterbova, M. Vlckova, P. Lassuthova, and A. Jahodova are supported by the Ministry of Health of the Czech Republic AZV NU20-04-00279.
Publisher Copyright:
© American Academy of Neurology.
PY - 2023/2/7
Y1 - 2023/2/7
N2 - Background and ObjectivesKCNH5 encodes the voltage-gated potassium channel EAG2/Kv10.2. We aimed to delineate the neurodevelopmental and epilepsy phenotypic spectrum associated with de novo KCNH5 variants.MethodsWe screened 893 individuals with developmental and epileptic encephalopathies for KCNH5 variants using targeted or exome sequencing. Additional individuals with KCNH5 variants were identified through an international collaboration. Clinical history, EEG, and imaging data were analyzed; seizure types and epilepsy syndromes were classified. We included 3 previously published individuals including additional phenotypic details.ResultsWe report a cohort of 17 patients, including 9 with a recurrent de novo missense variant p.Arg327His, 4 with a recurrent missense variant p.Arg333His, and 4 additional novel missense variants. All variants were located in or near the functionally critical voltage-sensing or pore domains, absent in the general population, and classified as pathogenic or likely pathogenic using the American College of Medical Genetics and Genomics criteria. All individuals presented with epilepsy with a median seizure onset at 6 months. They had a wide range of seizure types, including focal and generalized seizures. Cognitive outcomes ranged from normal intellect to profound impairment. Individuals with the recurrent p.Arg333His variant had a self-limited drug-responsive focal or generalized epilepsy and normal intellect, whereas the recurrent p.Arg327His variant was associated with infantile-onset DEE. Two individuals with variants in the pore domain were more severely affected, with a neonatal-onset movement disorder, early-infantile DEE, profound disability, and childhood death.DiscussionWe describe a cohort of 17 individuals with pathogenic or likely pathogenic missense variants in the voltage-sensing and pore domains of Kv10.2, including 14 previously unreported individuals. We present evidence for a putative emerging genotype-phenotype correlation with a spectrum of epilepsy and cognitive outcomes. Overall, we expand the role of EAG proteins in human disease and establish KCNH5 as implicated in a spectrum of neurodevelopmental disorders and epilepsy.
AB - Background and ObjectivesKCNH5 encodes the voltage-gated potassium channel EAG2/Kv10.2. We aimed to delineate the neurodevelopmental and epilepsy phenotypic spectrum associated with de novo KCNH5 variants.MethodsWe screened 893 individuals with developmental and epileptic encephalopathies for KCNH5 variants using targeted or exome sequencing. Additional individuals with KCNH5 variants were identified through an international collaboration. Clinical history, EEG, and imaging data were analyzed; seizure types and epilepsy syndromes were classified. We included 3 previously published individuals including additional phenotypic details.ResultsWe report a cohort of 17 patients, including 9 with a recurrent de novo missense variant p.Arg327His, 4 with a recurrent missense variant p.Arg333His, and 4 additional novel missense variants. All variants were located in or near the functionally critical voltage-sensing or pore domains, absent in the general population, and classified as pathogenic or likely pathogenic using the American College of Medical Genetics and Genomics criteria. All individuals presented with epilepsy with a median seizure onset at 6 months. They had a wide range of seizure types, including focal and generalized seizures. Cognitive outcomes ranged from normal intellect to profound impairment. Individuals with the recurrent p.Arg333His variant had a self-limited drug-responsive focal or generalized epilepsy and normal intellect, whereas the recurrent p.Arg327His variant was associated with infantile-onset DEE. Two individuals with variants in the pore domain were more severely affected, with a neonatal-onset movement disorder, early-infantile DEE, profound disability, and childhood death.DiscussionWe describe a cohort of 17 individuals with pathogenic or likely pathogenic missense variants in the voltage-sensing and pore domains of Kv10.2, including 14 previously unreported individuals. We present evidence for a putative emerging genotype-phenotype correlation with a spectrum of epilepsy and cognitive outcomes. Overall, we expand the role of EAG proteins in human disease and establish KCNH5 as implicated in a spectrum of neurodevelopmental disorders and epilepsy.
UR - http://www.scopus.com/inward/record.url?scp=85145325918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145325918&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000201492
DO - 10.1212/WNL.0000000000201492
M3 - Article
C2 - 36307226
AN - SCOPUS:85145325918
SN - 0028-3878
VL - 100
SP - E603-E615
JO - Neurology
JF - Neurology
IS - 6
ER -